ECHO-310: A phase 3, randomized trial of epacadostat plus nivolumab plus chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.

被引：1
|
作者：
Cohen, Ezra E. W.
Mehra, Ranee
Psyrri, Amanda
Bauman, Julie E.
Schaub, Richard
Zhou, Li
Li, Li
Jayaprakash, Vijayvel
Guigay, Joel
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Johns Hopkins Med Ctr, Baltimore, MD USA
[3] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Athens, Greece
[4] Univ Arizona, Coll Med, Tucson, AZ USA
[5] Incyte Corp, Wilmington, DE USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] Ctr Antoine Lacassagne, Nice, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS6092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6092
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC
    Rijavec, Erika
    Indini, Alice
    Ghidini, Michele
    Tomasello, Gianluca
    Cattaneo, Monica
    Barbin, Francesca
    Grossi, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 705 - 713
  • [2] A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.
    Cohen, Ezra E. W.
    Rischin, Danny
    Pfister, David G.
    Vermorken, Jan Baptist
    Zhao, Yufan
    Gowda, Hema
    Ge, Joy Yang
    Jin, Fan
    Harrington, Kevin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Alliance A022102: Randomized phase III trial of mFOLFIRINOX plus /- nivolumab vs. FOLFOX plus /- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)
    Park, Haeseong
    Geyer, Susan Michelle
    Klute, Kelsey
    Bleeker, Jonathan
    King, Daniel
    Strickland, Matthew
    Goodrich, Austin
    Carlisle, Destin
    Shergill, Ardaman
    O'Reilly, Eileen Mary
    Meyerhardt, Jeffrey A.
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
    Lara Jr, Primo N.
    Villanueva, Luis
    Ibanez, Carolina
    Erman, Mustafa
    Lee, Jae Lyun
    Heinrich, Daniel
    Lipatov, Oleg Nikolaevich
    Gedye, Craig
    Gokmen, Erhan
    Acevedo, Alejandro
    Semenov, Andrey
    Park, Se Hoon
    Gafanov, Rustem Airatovich
    Kose, Fatih
    Jones, Mark
    Du, Xiaoqi
    Munteanu, Mihaela
    Perini, Rodolfo
    Choueiri, Toni K.
    Motzer, Robert J.
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [5] Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
    Obara, G.
    Sun, J.
    Loo, D.
    Bohac, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S814 - S814
  • [6] Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
    Yang, Yunpeng
    Pan, Jianji
    Wang, Hui
    Zhao, Yuanyuan
    Qu, Shenhong
    Chen, Nianyong
    Chen, Xiaozhong
    Sun, Yan
    He, Xiaohui
    Hu, Chaosu
    Lin, Lizhu
    Yu, Qitao
    Wang, Siyang
    Wang, Guihua
    Lei, Feng
    Wen, Jiyu
    Yang, Kunyu
    Lin, Zhixiong
    Guo, Ye
    Chen, Shaoqing
    Huang, Xiaoming
    Wu, Yanjie
    Liang, Liang
    Chen, Chenqi
    Bai, Fan
    Ma, Xiaopeng
    Zhang, Yun
    Leaw, Shiangjiin
    Zhang, Li
    Fang, Wenfeng
    CANCER CELL, 2023, 41 (06) : 1061 - +
  • [7] Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME)
    Vermorken, J. B.
    Hitt, R.
    Geoffrois, L.
    Erfan, J.
    Kawecki, A.
    Zabolotnyy, D.
    Schueler, A.
    Knecht, R.
    Benasso, M.
    Kienzer, H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 324 - 324
  • [8] Nivolumab (N) plus ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651
    Argiris, A.
    Harrington, K.
    Tahara, M.
    Ferris, R. L.
    Gillison, M.
    Fayette, J.
    Daste, A.
    Koralewski, P.
    Nin, R. Mesia
    Saba, N. F.
    Mak, M.
    Avitia, M. A. Alvarez
    Guminski, A.
    Muller-Richter, U.
    Kiyota, N.
    Roberts, M.
    Khan, T. A.
    Miller-Moslin, K.
    Wei, L.
    Haddad, R. Robert
    ANNALS OF ONCOLOGY, 2021, 32 : S1310 - S1311
  • [9] The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab plus nivolumab vs. nivolumab in a real-world setting
    Billard, Karine
    Mortier, Laurent
    Dereure, Olivier
    Dalac, Sophie
    Montaudie, Henri
    Legoupil, Delphine
    Dutriaux, Caroline
    De Quatrebarbes, Julie
    Maubec, Eve
    Leccia, Marie-Therese
    Granel-Brocard, Florence
    Brunet-Possenti, Florence
    Arnault, Jean-Philippe
    Gaudy-Marqueste, Caroline
    Pages, Cecile
    Saiag, Philippe
    L'Orphelin, Jean-Matthieu
    Zehou, Ouidad
    Lesimple, Thierry
    Allayous, Clara
    Porcher, Raphael
    Oriano, Bastien
    Dalle, Stephane
    Lebbe, Celeste
    BRITISH JOURNAL OF DERMATOLOGY, 2025,
  • [10] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
    Lu, Shun
    Wang, Jie
    Yu, Yan
    Yu, Xinmin
    Hu, Yanping
    Ai, Xinghao
    Ma, Zhiyong
    Li, Xingya
    Zhuang, Wu
    Liu, Yunpeng
    Li, Weidong
    Cui, Jiuwei
    Wang, Dong
    Liao, Wangjun
    Zhou, Jianying
    Wang, Zhehai
    Sun, Yuping
    Qiu, Xiusong
    Gao, Jie
    Bao, Yuanyuan
    Liang, Liang
    Wang, Mengzhao
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522
12345